Metoprolol: Uses, Doses, Side Effects, and Drug Interactions

What Is Metoprolol and How Does It Work?

Metoprolol blocks beta-1 adrenergic receptors in the heart, reducing heart rate, myocardial contractility, and cardiac output. The result is lower blood pressure and less myocardial oxygen demand. At standard therapeutic doses it shows roughly 10-to-1 selectivity for beta-1 over beta-2 receptors, which means it is less likely than non-selective beta blockers to cause bronchospasm in patients with mild asthma, though it is not completely free of that risk.

Two distinct molecular salts reach pharmacy shelves. Metoprolol tartrate (Lopressor) is an immediate-release formulation dosed twice daily. Metoprolol succinate (Toprol-XL) uses an extended-release matrix and is dosed once daily. The salts are not interchangeable on a milligram-for-milligram basis, and prescribers should specify the salt when writing orders.

Both forms are metabolized by CYP2D6 in the liver. Poor metabolizers, who make up roughly 7 to 10% of European-ancestry populations, reach plasma concentrations five-fold higher than extensive metabolizers at the same dose. CYP2D6 pharmacogenomics data from the FDA underpin why some patients experience pronounced bradycardia at standard doses while others show minimal response.

FDA-Approved Indications

The FDA has approved metoprolol for four primary indications. Each carries a specific formulation preference.

Hypertension. Both tartrate and succinate carry approval. The 2017 ACC/AHA guideline defines hypertension as a blood pressure of 130/80 mmHg or higher and places beta blockers as first-line options specifically when heart failure, post-MI status, or high sympathetic tone is present, rather than as universal first-line agents. ACC/AHA 2017 Hypertension Guidelines reserve thiazides, ACE inhibitors, ARBs, and calcium-channel blockers for uncomplicated hypertension.

Stable angina. Metoprolol tartrate reduces anginal frequency by lowering heart rate and, therefore, myocardial oxygen demand. Beta blockers remain a Class I recommendation for chronic stable angina in patients without contraindications.

Heart failure with reduced ejection fraction (HFrEF). Only metoprolol succinate (Toprol-XL) carries this indication. The MERIT-HF trial enrolled 3,991 patients with NYHA class II, III HFrEF and randomized them to succinate versus placebo on top of standard therapy. All-cause mortality was 34% lower in the metoprolol group (7.2% vs. 11.0% annual mortality rate) [1]. This remains one of the most cited mortality benefits in cardiology.

Post-myocardial infarction. Starting oral metoprolol within the first 24 hours of an ST-elevation MI reduces infarct size and ventricular arrhythmias. The COMMIT trial (N=45,852) showed that early intravenous metoprolol followed by oral dosing reduced ventricular fibrillation by 17% versus placebo, though it also increased the risk of cardiogenic shock in hemodynamically unstable patients [2]. Clinicians should confirm hemodynamic stability before initiating the drug in the acute setting.

Metoprolol Doses by Indication

Dosing varies considerably by indication and formulation. The table below summarizes standard adult regimens.

Hypertension (succinate, once daily): Start at 25 to 100 mg; titrate to a maximum of 400 mg/day based on blood pressure and heart rate response.

Hypertension (tartrate, twice daily): Start at 50 mg twice daily; may increase to 100 mg twice daily.

Stable angina (tartrate): 50 to 200 mg/day in two divided doses.

HFrEF (succinate only): Begin at 12.5 mg once daily for NYHA class III, IV, or 25 mg once daily for NYHA class II. Double the dose every two weeks as tolerated, targeting 200 mg/day.

Post-MI (tartrate): 100 mg twice daily, initiated once hemodynamic stability is confirmed.

Renal impairment does not substantially alter metoprolol pharmacokinetics because less than 5% of the drug is excreted unchanged. Hepatic impairment, by contrast, reduces clearance enough that starting at the lower end of each range and titrating cautiously is standard practice.

Side Effects and Safety Profile

Metoprolol is generally well tolerated. The side effects that appear most consistently in placebo-controlled trials are fatigue (reported in roughly 10% of patients), bradycardia, and cold extremities secondary to reduced peripheral blood flow.

Sexual dysfunction. A meta-analysis published in JAMA (Brixius et al.) found that beta blockers as a class carry a modest but real increased risk of erectile dysfunction compared with placebo. The mechanism involves decreased penile blood flow from beta-2 blockade and possible central effects.

Masking hypoglycemia. Metoprolol blunts the tachycardia response to hypoglycemia, which matters for insulin-dependent diabetic patients. Sweating, a non-adrenergic signal, remains intact and can still warn patients of a dropping glucose. Prescribers in diabetes management routinely note this when co-managing cardiometabolic patients on both insulin and metoprolol.

CNS effects. Because metoprolol is lipophilic, it crosses the blood-brain barrier more readily than hydrophilic beta blockers like atenolol. Sleep disturbance and vivid dreams occur in a minority of patients, estimated at 1 to 3% in post-market surveillance data.

Abrupt discontinuation. Stopping metoprolol suddenly can cause rebound hypertension and angina through adrenergic receptor upregulation. The drug should be tapered over one to two weeks whenever possible.

Contraindications include: severe bradycardia (resting heart rate <45 bpm), sick-sinus syndrome without a pacemaker, decompensated heart failure requiring inotropic support, and known hypersensitivity.

Drug Interactions

CYP2D6 inhibitors raise metoprolol plasma levels and can cause symptomatic bradycardia or hypotension. Clinically significant inhibitors include fluoxetine, paroxetine, bupropion, and quinidine. A patient stable on 100 mg/day of metoprolol who starts paroxetine 20 mg/day may experience a two-to-five-fold rise in metoprolol exposure.

Calcium channel blockers deserve special attention. Combining metoprolol with verapamil or diltiazem (the non-dihydropyridine subclass) can cause additive AV-node suppression, leading to symptomatic bradycardia or complete heart block. This combination should be avoided unless continuous cardiac monitoring is available.

Clonidine co-administration carries a rebound hypertension risk specifically at clonidine discontinuation. The beta blocker eliminates the compensatory tachycardia that would otherwise signal the problem, and blood pressure may spike precipitously. If both drugs must be stopped, withdraw metoprolol before clonidine.

Statins, the most common co-prescription in cardiometabolic patients, do not significantly interact with metoprolol pharmacokinetically. Atorvastatin (Lipitor), rosuvastatin (Crestor), simvastatin (Zocor), and ezetimibe (Zetia) can all be co-administered without dose adjustment of metoprolol.

Metoprolol in a Cardiometabolic Regimen: Statins and Ezetimibe

Most patients who need metoprolol for cardiovascular disease also carry elevated LDL cholesterol. Understanding how the major lipid-lowering agents work alongside beta blocker therapy matters for anyone managing or receiving a complete cardiometabolic regimen.

Atorvastatin (Lipitor). Atorvastatin is a high-intensity statin that inhibits HMG-CoA reductase. The ASCOT-LLA trial (N=10,305) showed that atorvastatin 10 mg/day reduced major cardiovascular events by 36% versus placebo in hypertensive patients with at least three additional risk factors, with a median follow-up of 3.3 years [3]. The 2018 ACC/AHA Cholesterol Guidelines recommend high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) as first-line treatment for patients with established atherosclerotic cardiovascular disease. ACC/AHA 2018 Cholesterol Guideline states: "High-intensity statin therapy should be initiated or continued in patients 75 years of age or younger with clinical ASCVD." Atorvastatin is metabolized by CYP3A4, not CYP2D6, so it does not affect metoprolol levels.

Rosuvastatin (Crestor). Rosuvastatin is the most potent statin per milligram. The JUPITER trial (N=17,802) randomized individuals with LDL <130 mg/dL but elevated high-sensitivity CRP to rosuvastatin 20 mg/day versus placebo. Rosuvastatin reduced the combined endpoint of MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56 to 95% CI 0.46, 0.69, P<0.00001) over a median of 1.9 years [4]. Rosuvastatin is minimally metabolized by CYP2C9 and is not a CYP2D6 substrate, so co-administration with metoprolol raises no pharmacokinetic concern.

Simvastatin (Zocor). Simvastatin is a moderate-to-high-intensity statin at doses of 20 to 40 mg and a high-intensity agent at 80 mg, though the FDA issued a 2011 safety communication restricting the 80 mg dose to patients already taking it for 12 months without myopathy [5]. The 4S trial (N=4,444), published in The Lancet in 1994, showed that simvastatin 20 to 40 mg reduced total mortality by 30% versus placebo over 5.4 years in patients with coronary heart disease [6]. Simvastatin is a CYP3A4 substrate, and co-administration with strong CYP3A4 inhibitors dramatically raises myopathy risk; metoprolol is not a CYP3A4 inhibitor, so no dose adjustment of simvastatin is needed because of the beta blocker.

Ezetimibe (Zetia). Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, reducing cholesterol absorption by roughly 54% and LDL-C by 15 to 20% as monotherapy. The IMPROVE-IT trial (N=18,144) added ezetimibe 10 mg to simvastatin 40 mg versus simvastatin alone in post-ACS patients. The combination reduced LDL-C from a median of 69.5 mg/dL to 53.7 mg/dL and cut the primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) by 6.4% relative risk reduction over 7 years [7]. Ezetimibe has no clinically relevant interactions with metoprolol.

A practical tiering framework for cardiometabolic prescribing. When building a regimen for a patient with hypertension plus established ASCVD, the evidence supports this sequence: (1) start a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) as the LDL backbone; (2) add ezetimibe 10 mg if LDL-C remains above 70 mg/dL on maximally tolerated statin; (3) layer in metoprolol succinate when heart failure, post-MI status, angina, or uncontrolled sympathetic-mediated hypertension is present; (4) add an ACE inhibitor or ARB if blood pressure or albuminuria warrants it. Metoprolol sits in the third tier, not the first, because the primary cardiometabolic mortality driver is LDL-C reduction, and statin therapy has the broadest event-reduction data across unselected high-risk populations.

Monitoring Parameters

After starting or up-titrating metoprolol, the following parameters warrant regular assessment.

Heart rate. A resting rate of 55, 70 bpm is generally the therapeutic target for heart failure patients; below 50 bpm warrants dose reduction or cardiology referral.

Blood pressure. Check 2 to 4 weeks after each dose change. Target is <130/80 mmHg per 2017 ACC/AHA criteria for most patients with ASCVD.

Symptoms of hypotension. Dizziness on standing suggests orthostatic hypotension, particularly in older adults or those also taking diuretics.

Lipid panel. Annual fasting lipid panels are standard for patients on statin therapy. The ACC/AHA 2018 guidelines recommend checking fasting lipids 4 to 12 weeks after starting a statin, then every 3 to 12 months as needed, specifically to confirm adherence and response.

Liver enzymes. Routine transaminase monitoring is no longer required for statins in otherwise healthy patients per the FDA's 2012 label change, though a baseline measurement is reasonable. FDA Drug Safety Communication on Statin Labels.

Blood glucose. Beta blockers modestly blunt insulin sensitivity. A 2007 meta-analysis in Diabetes Care (N=94,492 patients across 12 trials) found that beta blockers increased incident diabetes by 22% compared with other antihypertensive classes [8]. Monitoring HbA1c annually in pre-diabetic patients on metoprolol is appropriate.

Special Populations

Pregnancy. Metoprolol is classified as a category C drug under the old FDA system. It crosses the placenta and has been associated with intrauterine growth restriction and neonatal bradycardia when used near term. Labetalol is typically preferred for hypertension in pregnancy, though metoprolol may be continued if benefits outweigh risks in women with HFrEF or post-MI status.

Older adults. The 2023 American Geriatrics Society Beers Criteria does not list metoprolol as a potentially inappropriate medication in older adults, unlike some other beta blockers. However, the increased prevalence of sick-sinus syndrome and AV-node disease in this population means a baseline ECG before initiating therapy is prudent.

Chronic kidney disease. No dose adjustment is needed for any stage of CKD because hepatic metabolism accounts for more than 95% of elimination.

Asthma and COPD. Metoprolol's beta-1 selectivity makes it relatively safer than propranolol in obstructive lung disease, but the selectivity is not absolute. A 2002 Cochrane review (17 randomized trials) confirmed that cardioselective beta blockers did not significantly reduce FEV1 or cause adverse respiratory effects in mild-to-moderate reversible airway disease [9]. Severe or unstable asthma remains a relative contraindication.

Switching Between Formulations

A prescriber moving a patient from metoprolol tartrate to succinate should note that the two salts carry different dose equivalences. Metoprolol tartrate 50 mg twice daily (100 mg total) is roughly equivalent to metoprolol succinate 100 mg once daily. The conversion is 1:1 on a total daily milligram basis, but patient response may differ slightly because of the pharmacokinetic profile. Checking resting heart rate and blood pressure one to two weeks after switching confirms clinical equivalence.

Cost and Access

Generic metoprolol tartrate costs roughly $4, 10 for a 30-day supply at major pharmacies, making it one of the least expensive cardiovascular drugs available. Generic metoprolol succinate runs $10, 25 for 30 days. Atorvastatin (generic) is similarly inexpensive at $5, 15 per month; rosuvastatin generic runs $15, 30; ezetimibe generic costs approximately $15, 35. Simvastatin generic is under $10 at most major pharmacy chains, making it the lowest-cost statin option for patients without insurance. Together, a full cardiometabolic regimen of metoprolol succinate plus high-intensity statin plus ezetimibe can be assembled for under $60 per month in generic form.